Background We conducted a systematic review and meta-analysis of the cardiovascular,
kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among …

Type 2 diabetes mellitus (T2DM) is a highly prevalent health condition in the aging
population. Older adults with T2DM have higher risks of cardiovascular disease, heart failure …

Importance Sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy has been associated
with cardiovascular benefits and a few adverse events; however, whether the comparative …

Background and aims Sodium-glucose co-transporter-2 inhibitors (SGLT2i) may have
important benefits for the elderly with type 2 diabetes (T2D), however some safety concerns …

Acute kidney injury (AKI) and diabetes mellitus (DM) are public health problems that cause a
high socioeconomic burden worldwide. In recent years, the landscape of AKI etiology has …

OBJECTIVE Type 2 diabetes (T2D) increases dementia risk, but clear evidence to
recommend interventions that can mitigate that risk remains lacking. This population-based …

Importance The association between sodium-glucose transport protein 2 inhibitor (SGLT2i)
use and the incidence of acute kidney injury (AKI) remains controversial. The benefits of …

Aim Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) are particularly effective in
preventing adverse outcomes of heart failure and chronic kidney disease, which are highly …

Background Sodium glucose co-transporter-2 (SGLT2) inhibitors improve long-term
cardiovascular and renal outcomes in individuals with type 2 diabetes. However, the safety …

Background Contrast-induced acute kidney injury (CI-AKI) is a common complication of
patients undergoing percutaneous coronary intervention (PCI). Data regarding the influence …